

UC DAVIS HEALTH

Date: Friday, April 4, 2025

Time: 7:00 AM - 11:30 AM

Learning Format: Live Activity

Presentation Information:

- Eye Center Grand Rounds and Comparative Ophthalmology Series
 - RETINA GRAND ROUNDS - 4/4/2025

Description:

Eye Center Grand Rounds and Comparative Ophthalmology Series

Objective(s): 1 Manage complex ophthalmology cases according to best-practice guidelines, resulting in improved physician competency. 2 Critically analyze emerging data from national and international clinical research and best practices to enhance diagnostic and therapeutic treatment and care. 3 Utilize the AREDS classification of AMD severity and the additional risk of the presence of reticular pseudodrusen (RPD). 4 Recognize the effects of the diet and the effects of the AREDS/AREDS2 supplements on AMD progression. 5 Be aware of the prevalence of Charles Bonnet Syndrome, or visual hallucinations in persons with AMD. 6 Recognize that macular telangiectasis type 2 (Mac Tel) is now considered a neuroglial -vascular degeneration. 7 Understand that a natural history study provided data to develop a clinical outcome of area of ellipsoid zone loss on OCT for a clinical trial.

Location:

Faculty Disclosures:

Emily Chew, MD (Nothing to disclose - 01/22/2025)

Jennifer P Tingley, MD (Nothing to disclose - 01/29/2025)

Mark McAllister, MD (Nothing to disclose - 03/04/2025)

Neda Dastgheyb, MD (Nothing to disclose - 02/28/2025)

[Download Handout](#)

Series Objectives:

- 1 Manage complex ophthalmology cases according to best-practice guidelines, resulting in improved physician competency.
- 2 Critically analyze emerging data from national and international clinical research and best practices to enhance diagnostic and therapeutic treatment and care.

Session Objectives:

- 1 Manage complex ophthalmology cases according to best-practice guidelines, resulting in improved physician competency.
- 2 Critically analyze emerging data from national and international clinical research and best practices to enhance diagnostic and therapeutic treatment and care.
- 3 Utilize the AREDS classification of AMD severity and the additional risk of the presence of reticular pseudodrusen (RPD).
- 4 Recognize the effects of the diet and the effects of the AREDS/AREDS2 supplements on AMD progression.
- 5 Be aware of the prevalence of Charles Bonnet Syndrome, or visual hallucinations in persons with AMD.
- 6 Recognize that macular telangiectasis type 2 (Mac Tel) is now considered a neuroglial -vascular degeneration.

7 Understand that a natural history study provided data to develop a clinical outcome of area of ellipsoid zone loss on OCT for a clinical trial.

Accreditation Statement:

University of California, Davis Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

UC Davis Health designates this Live Activity for a maximum of 3.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

UC Davis Health designates this live activity for a maximum of 3.00 Participation Hour(s).

Mitigation Statement:

University of California, Davis Health Continuing Medical Education adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Shelley Palumbo, MS, SLP	Other Planning Committee Member	Nothing to disclose - 12/19/2024
Mark Mannis, MD	Course Director	Nothing to disclose - 02/24/2025
Parisa Emami Naeini, MD	Course Director	Consultant-Alimera Consultant-Bausch & Lomb (Any division) Consultant-Genentech (Any division) Consultant-Regeneron Pharmaceuticals, Inc. - 12/18/2024
Jennifer P Tingley, MD	Faculty	Nothing to disclose - 01/29/2025
Neda Dastgheyb, MD	Faculty	Nothing to disclose - 02/28/2025
Emily Chew, MD	Faculty	Nothing to disclose - 01/22/2025
Mark McAllister, MD	Faculty	Nothing to disclose - 03/04/2025

Commercial Support:

This activity is not commercially supported.